Full scope AAV services

Discover our 'plug and play' AAV platform

We partner with cell and gene therapy companies to provide innovative, end-to-end adeno-associated virus (AAV) platform process development and industry-leading manufacturing services to deliver life-saving and life-altering treatments to all.

Our ‘plug and play’ AAV platform is commercially ready, with services that cover construct design through to CGMP manufacturing, accompanied by the full suite of analytical support. Our focus is on achieving both high titres and high purity vectors.

To learn more about our AAV process, please visit our AAV Centre of Excellence.

Results that speak for themselves

Optimised processes

We have optimised our transfection process to achieve a suspension bioreactor titre that consistently reaches up to 1E15vg/l; that’s almost two orders of magnitude above the industry standard.

>1E15

vg/L

>90%

full capsids

Proven performance

We have demonstrated consistent performance and quality in 800+ batches with 500+ constructs, across multiple genomes, AAV serotypes, and production scales.

850+

batches

550

constructs

Commercial quality

Through continual improvement, we have refined our platform to achieve over 90% full vector at scales of up to 2,000L.

2x

productivity

2,000

litre capacity

What makes our AAV platform unique

Our team features the extensive technical know-how and deep expertise needed to fully understand the challenges of AAV manufacturing. Our strong quality culture permeates the entire organization and demands that we achieve at the highest level through all functions.

Because of our expertise, continued pursuit of innovation, and our team members’ accomplished backgrounds, we are able to offer:-

HIGH PERFORMANCE

>1E15 vg/L

bioreactor titer demonstrated across >10 serotypes and multiple genes of interest

HIGH QUALITY

>90%

full AAV vector achieved

ANALYTICAL DEVELOPMENT

>45 methods

developed for full vector characterization quality control and stability testing

REGULATORY EXPERIENCE

6 successful IND/CTA

submissions accepted

COMMERCIAL READINESS

optimised manufacturing process scaled to

500 & 2000L

YIELD

>1E17 vg

of drug substances from 500L batches